ConductScience.org, home

Paper40121031

PLS-α-GalCer: a novel targeted glycolipid therapy for solid tumors.

Burks J and 6 others. J Immunother Cancer, 2025. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. PLS-α-GalCer: a novel targeted glycolipid therapy for solid tumors. Papers, record 40121031. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40121031

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
PLS-α-GalCer: a novel targeted glycolipid therapy for solid tumors.
PubMed
Journal
J Immunother Cancer
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2025-05-14
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Burks JJulianhttps://orcid.org/0000-0002-8760-766X
2Tiwary SShweta
3Stevens DMDavid M
4Skoczen SLSarah L
5Kularatne RNRuvanthi N
6Stern STStephan T
7Berzofsky JAJay Ahttps://orcid.org/0000-0002-0342-3194

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
GalactosylceramidesMajor topic
NeoplasmsMajor topic
Pancreatic NeoplasmsMajor topic
GlycolipidsMajor topic
Animals
Mice
Humans
Female
Cell Line, Tumor
Natural Killer T-Cells

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
75N91019D00024NCI NIH HHSUnited StatesPubMedPubMed
F22CA000024NIHNIH RePORTER
ZIASC004020NIHNIH RePORTER
ZICBC010936NIHNIH RePORTER

Download CSV of grants

References62

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132841040Application of a Scavenger Receptor A1-Targeted Polymeric Prodrug Platform for Lymphatic Drug Delivery in HIV.Mol Pharm2020https://conductscience.org/library/papers/32841040PubMed
215756017A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.Clin Cancer Res2005https://conductscience.org/library/papers/15756017PubMed
330568305Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial.Nature2019https://conductscience.org/library/papers/30568305PubMed
428860937A brief review of clinical trials involving manipulation of invariant NKT cells as a promising approach in future cancer therapies.Cent Eur J Immunol2017https://conductscience.org/library/papers/28860937PubMed
510199836Distinct scavenger receptor expression and function in the human CD14(+)/CD16(+) monocyte subset.Am J Physiol1999https://conductscience.org/library/papers/10199836PubMed
619055947The role of NKT cells in tumor immunity.Adv Cancer Res2008https://conductscience.org/library/papers/19055947PubMed
724507759A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients.J Ovarian Res2014https://conductscience.org/library/papers/24507759PubMed
816138189Activation or anergy: NKT cells are stunned by alpha-galactosylceramide.J Clin Invest2005https://conductscience.org/library/papers/16138189PubMed
98866665KRN7000, a novel immunomodulator, and its antitumor activities.Oncol Res1995https://conductscience.org/library/papers/8866665PubMed
1031244823α-GalCer and iNKT Cell-Based Cancer Immunotherapy: Realizing the Therapeutic Potentials.Front Immunol2019https://conductscience.org/library/papers/31244823PubMed
1112077264Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.J Immunol2002https://conductscience.org/library/papers/12077264PubMed
1224440852Tumor-induced perturbations of cytokines and immune cell networks.Biochim Biophys Acta2014https://conductscience.org/library/papers/24440852PubMed
1321675859Macrophage scavenger receptor A mediates the uptake of gold colloids by macrophages in vitro.Nanomedicine (Lond)2011https://conductscience.org/library/papers/21675859PubMed
1432833941T-Cell Immunity in Pancreatic Cancer.Pancreas2020https://conductscience.org/library/papers/32833941PubMed
1528678778An immunogenic personal neoantigen vaccine for patients with melanoma.Nature2017https://conductscience.org/library/papers/28678778PubMed
1611101862NKT cells and tumor immunity--a double-edged sword.Nat Immunol2000https://conductscience.org/library/papers/11101862PubMed
1733969083Immunotherapy for pancreatic cancer.World J Clin Cases2021https://conductscience.org/library/papers/33969083PubMed
1823064364Scavenger receptors target glycolipids for natural killer T cell activation.J Clin Invest2012https://conductscience.org/library/papers/23064364PubMed
1934465781A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity.Nat Commun2021https://conductscience.org/library/papers/34465781PubMed
2032328176DNT Cell-based Immunotherapy: Progress and Applications.J Cancer2020https://conductscience.org/library/papers/32328176PubMed

See all 62 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn PapersSource
42894632Poloxamer-Based Th1-Biased NKT Cell Nano-Agonist for Tumor Immunotherapy.Int J Nanomedicine2026https://conductscience.org/library/papers/42894632PubMed
42819957All-Hydrocarbon Macrocycle Enables Highly Potent Th1-Biased NKT Cell Agonists for Immunotherapy.JACS Au2026https://conductscience.org/library/papers/42819957PubMed
41755879Highly Potent Th1-Type NKT Cell Agonists as Immunotherapeutic Agents via Conformational Restriction Design.JACS Au2026https://conductscience.org/library/papers/41755879PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40121031

GET https://conductscience.org/api/papers/v1/40121031/references?page=2